Marc Michel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Marc Michel has a total of 78 co-authors. Here are the top co-authors by number of shared publications:
- Charlotte Proudhon
Circulating Tumor Biomarkers Laboratory, Institut Curie, PSL Research University, Paris, France
37 shared publications - François-Clément Bidard
Translational Research Department, Laboratory of Circulating Tumor Biomarkers, Inserm CIC 1428, Institut Curie, Paris, France
28 shared publications - Marc-Henri Stern
Institut Curie
25 shared publications - Luc Cabel
Institut Curie
24 shared publications - Olivier Lantz
Institut Curie
24 shared publications - Anissa Mechri
INSERM U934, CNRS UMR3215, Institut Curie, PSL Research University, Paris, France
23 shared publications
Latest Publications
- 7 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
La méthylation de l'ADN tumoral circulant comme biomarqueur prédictif multicancer
Ce travail de thèse a pour objectif l’étude du potentiel de la méthylation de l'ADN circulant comme biomarqueur tumoral universel, et le développement de nouvelles stratégies hautement sensibles pour la détection, dans le sang, de signatures spécifiques au cancer. Nous proposons la mise en œuvre d’un test diagnostique non invasif, hautement sensible et utile pour le suivi de tous les types de cancer, en temps réel. À cette fin, nous examinons en profondeur les performances d'un test ciblant les changements de méthylation de l'ADN tumoral circulant et développons une méthode d'analyse « clef en main » permettant de classer les échantillons selon leur statut sain ou tumoral, leur tissu d'origine, ainsi qu'une analyse quantitative de leur charge tumorale.
- 7 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
La méthylation de l'ADN tumoral circulant comme biomarqueur prédictif multicancer
Ce travail de thèse a pour objectif l’étude du potentiel de la méthylation de l'ADN circulant comme biomarqueur tumoral universel, et le développement de nouvelles stratégies hautement sensibles pour la détection, dans le sang, de signatures spécifiques au cancer. Nous proposons la mise en œuvre d’un test diagnostique non invasif, hautement sensible et utile pour le suivi de tous les types de cancer, en temps réel. À cette fin, nous examinons en profondeur les performances d'un test ciblant les changements de méthylation de l'ADN tumoral circulant et développons une méthode d'analyse « clef en main » permettant de classer les échantillons selon leur statut sain ou tumoral, leur tissu d'origine, ainsi qu'une analyse quantitative de leur charge tumorale.
- Open Access
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S9 from Noninvasive Multicancer Detection Using DNA Hypomethylation of LINE-1 Retrotransposons
Fig S9. Age has a minor effect on L1PA DNA methylation patterns and is not a confounding factor in this study
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S9 from Noninvasive Multicancer Detection Using DNA Hypomethylation of LINE-1 Retrotransposons
Fig S9. Age has a minor effect on L1PA DNA methylation patterns and is not a confounding factor in this study
- Open Access
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S8 from Noninvasive Multicancer Detection Using DNA Hypomethylation of LINE-1 Retrotransposons
Fig S8. DIAMOND profiles and performances in the validation versus discovery cohorts
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S8 from Noninvasive Multicancer Detection Using DNA Hypomethylation of LINE-1 Retrotransposons
Fig S8. DIAMOND profiles and performances in the validation versus discovery cohorts
- Open Access
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S10 from Noninvasive Multicancer Detection Using DNA Hypomethylation of LINE-1 Retrotransposons
Fig S10. Comparison of multiple classifiers (expert, all, stack and blind models) and prognostic value of L1PA hypomethylation
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S10 from Noninvasive Multicancer Detection Using DNA Hypomethylation of LINE-1 Retrotransposons
Fig S10. Comparison of multiple classifiers (expert, all, stack and blind models) and prognostic value of L1PA hypomethylation
- Open Access
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S8 from Noninvasive Multicancer Detection Using DNA Hypomethylation of LINE-1 Retrotransposons
Fig S8. DIAMOND profiles and performances in the validation versus discovery cohorts
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S8 from Noninvasive Multicancer Detection Using DNA Hypomethylation of LINE-1 Retrotransposons
Fig S8. DIAMOND profiles and performances in the validation versus discovery cohorts
- Open Access
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S9 from Noninvasive Multicancer Detection Using DNA Hypomethylation of LINE-1 Retrotransposons
Fig S9. Age has a minor effect on L1PA DNA methylation patterns and is not a confounding factor in this study
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S9 from Noninvasive Multicancer Detection Using DNA Hypomethylation of LINE-1 Retrotransposons
Fig S9. Age has a minor effect on L1PA DNA methylation patterns and is not a confounding factor in this study
- Open Access
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Noninvasive Multicancer Detection Using DNA Hypomethylation of LINE-1 Retrotransposons
Fig S4. DIAMOND features: CpG calling and contribution of CG positions or haplotypes
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Noninvasive Multicancer Detection Using DNA Hypomethylation of LINE-1 Retrotransposons
Fig S4. DIAMOND features: CpG calling and contribution of CG positions or haplotypes
- Open Access
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Tables S1-S22 from Noninvasive Multicancer Detection Using DNA Hypomethylation of LINE-1 Retrotransposons
Table S1. Targeted bisulfite sequencing primers Table S2. Target copies and CpG sites relative to the number of sequencing reads Table S3. Statistical results of global methylation differences between healthy samples and cancer subgroups using Mann–Whitney U test Table S4. List of plasma samples. Sample IDs were not known to anyone outside the research group Table S5. Statistical results of proportion differences between healthy samples and cancer subgroups for the 372 haplotypes using Mann–Whitney U test Table S6. List of paired plasma and tissues samples and their spearman correlation for various features Table S7. Breast cancer subtype composition of M0 and M+ subgroups in C1 and C2 Table S8. Mutation screening of ovarian cancer samples from the discovery cohort Table S9. Statistical results of proportion differences between healthy samples from C1 and C2 for 14 haplotypes selected using Mann–Whitney U test Table S10. Statistical results of global methylation differences between healthy samples and cancer subgroups from C1 and C2 using Mann–Whitney U test Table S11. Statistical results of proportion differences between healthy samples and cancer subgroups from C1 and C2 for 14 haplotypes selected using Mann–Whitney U test Table S12. Statistical results of global methylation differences between original data and age-adjusted data using Mann–Whitney U test Table S13. Statistical results of global methylation differences between cancer stages using Mann–Whitney U test Table S14. Statistical results of global methylation differences between primary and metastatic tissues using Mann–Whitney U test Table S15. Statistical results of Genome-wide z-score differences between healthy samples and cancer subgroups using Mann–Whitney U test Tables S16-S22. Cancer prediction and sample labelling with the 2-step classification integrating CNA analysis - healthy vs each type of model
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables S1-S22 from Noninvasive Multicancer Detection Using DNA Hypomethylation of LINE-1 Retrotransposons
Table S1. Targeted bisulfite sequencing primers Table S2. Target copies and CpG sites relative to the number of sequencing reads Table S3. Statistical results of global methylation differences between healthy samples and cancer subgroups using Mann–Whitney U test Table S4. List of plasma samples. Sample IDs were not known to anyone outside the research group Table S5. Statistical results of proportion differences between healthy samples and cancer subgroups for the 372 haplotypes using Mann–Whitney U test Table S6. List of paired plasma and tissues samples and their spearman correlation for various features Table S7. Breast cancer subtype composition of M0 and M+ subgroups in C1 and C2 Table S8. Mutation screening of ovarian cancer samples from the discovery cohort Table S9. Statistical results of proportion differences between healthy samples from C1 and C2 for 14 haplotypes selected using Mann–Whitney U test Table S10. Statistical results of global methylation differences between healthy samples and cancer subgroups from C1 and C2 using Mann–Whitney U test Table S11. Statistical results of proportion differences between healthy samples and cancer subgroups from C1 and C2 for 14 haplotypes selected using Mann–Whitney U test Table S12. Statistical results of global methylation differences between original data and age-adjusted data using Mann–Whitney U test Table S13. Statistical results of global methylation differences between cancer stages using Mann–Whitney U test Table S14. Statistical results of global methylation differences between primary and metastatic tissues using Mann–Whitney U test Table S15. Statistical results of Genome-wide z-score differences between healthy samples and cancer subgroups using Mann–Whitney U test Tables S16-S22. Cancer prediction and sample labelling with the 2-step classification integrating CNA analysis - healthy vs each type of model
- Open Access
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from Noninvasive Multicancer Detection Using DNA Hypomethylation of LINE-1 Retrotransposons
Fig S7. Extraction of L1PA DNA hypomethylation signal from whole genome data
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from Noninvasive Multicancer Detection Using DNA Hypomethylation of LINE-1 Retrotransposons
Fig S7. Extraction of L1PA DNA hypomethylation signal from whole genome data
- Open Access
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S11 from Noninvasive Multicancer Detection Using DNA Hypomethylation of LINE-1 Retrotransposons
Fig S11. 2 step-models integrating CNA signal extracted from DIAMOND data
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S11 from Noninvasive Multicancer Detection Using DNA Hypomethylation of LINE-1 Retrotransposons
Fig S11. 2 step-models integrating CNA signal extracted from DIAMOND data